<p>Nkarta, Inc.（纳斯达克代码：NKTX - 免费报告）- 威廉·布莱尔的投资分析师在 11 月 11 日星期二向投资者发布的研究报告中上调了对 Nkarta 2025 财年每股收益的预期。威廉·布莱尔的分析师 S. Corwin 现在预计该公司 2025 财年每股收益为（$1.36），高于之前预测的（$1.38）。市场普遍预计 Nkarta 当前全年的每股收益为（$1.70）。威廉·布莱尔还对 Nkarta 2026 财年的每股收益进行了预测，预计为（$1.29）。</p>
<p>Nkarta（纳斯达克代码：NKTX - 获取免费报告）在 11 月 10 日星期一发布了季度财报。该公司报告的季度每股收益为（$0.29），超出市场普遍预期的（$0.32）$0.03。</p>
<p>其他股票研究分析师也对该公司发布了研究报告。Weiss Ratings 在 10 月 31 日星期五的研究报告中重新发布了对 Nkarta 股票的 “卖出（d-）” 评级。Needham &amp; Company LLC 在 8 月 13 日星期三的报告中重申了对 Nkarta 的 “买入” 评级，并给出了$10.00 的目标价。华尔街 Zen 在 10 月 25 日星期六的研究报告中将 Nkarta 的评级从 “卖出” 上调至 “持有”。最后，Stifel Nicolaus 在周二的研究报告中将 Nkarta 的目标价从$12.00 下调至$11.00，并对该公司设定了 “买入” 评级。四位投资分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为$13.25。</p>
<p><strong>获取我们对 Nkarta 的最新股票分析</strong></p>
<h2>Nkarta 股票下跌 2.5%</h2>
<p>纳斯达克 NKTX 在星期四开盘价为$1.96。该公司的 50 日简单移动平均为$2.13，200 日简单移动平均为$2.01。Nkarta 的 12 个月低点为$1.31，12 个月高点为$3.18。该公司的市值为$139.22 百万，市盈率为-1.42，贝塔值为 0.86。</p>
<h2>机构投资者对 Nkarta 的看法</h2>
<p>机构投资者和对冲基金最近调整了对该股票的持有。Savant Capital LLC 在第二季度购买了价值约$36,000 的 Nkarta 新头寸。SG Americas Securities LLC 在第三季度将其在 Nkarta 的持仓增加了 35.0%。SG Americas Securities LLC 目前拥有 23,663 股该公司股票，价值$49,000，此前在上个季度又增持了 6,141 股。CWM LLC 在第一季度将其在 Nkarta 的持仓增加了 3,437.3%。CWM LLC 目前拥有 28,157 股该公司股票，价值$52,000，此前在上个季度又增持了 27,361 股。Bailard Inc.在第三季度购买了价值约$61,000 的 Nkarta 新头寸。最后，Cerity Partners LLC 在第一季度购买了价值约$55,000 的 Nkarta 新头寸。80.54% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于 Nkarta</h2>
<p>（获取免费报告）</p>
<p>Nkarta, Inc.是一家临床阶段的生物制药公司，开发和商业化用于癌症和自身免疫疾病治疗的自然杀伤细胞疗法。该公司的主要产品候选者是 NKX019，一种靶向 CD19 抗原的嵌合抗原受体 - 自然杀伤细胞（CAR NK），目前正在进行针对复发/难治性（r/r）非霍奇金淋巴瘤的 1 期临床试验，以及针对狼疮性肾炎的治疗。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票比 Nkarta 更好</li>
<li>动量投资与长期投资的区别</li>
<li>关于 Holding 的抛售结束的三大理由及新高即将到来</li>
<li>什么是 MarketRank™？如何使用它</li>
<li>随着沃伦·巴菲特接近退出，伯克希尔积累了创纪录的现金</li>
<li>现在购买的三只巨型成长股</li>
<li>稀土股票：并非真正的停火</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TktUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TktUWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Nkarta 吗？</h2>
<p>在你考虑 Nkarta 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Nkarta 并不在名单上。</p>
<p>虽然 Nkarta 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

NKTX

<p>威廉·布莱尔将 Nkarta 的 2025 财年每股收益（EPS）预估从（$1.38）上调至（$1.36）。市场共识全年每股收益为（$1.70）。2026 财年每股收益预计为（$1.29）。Nkarta 的股票评级为适度买入，市场共识目标价为$13.25。机构投资者持有该股票的 80.54%。Nkarta 开发用于癌症和自身免疫疾病的 CAR NK 疗法</p>

<p>Nkarta, Inc. (NASDAQ:NKTX - Free Report) - Investment analysts at William Blair lifted their FY2025 earnings per share estimates for Nkarta in a research note issued to investors on Tuesday, November 11th. William Blair analyst S. Corwin now anticipates that the company will earn ($1.36) per share for the year, up from their previous forecast of ($1.38). The consensus estimate for Nkarta's current full-year earnings is ($1.70) per share. William Blair also issued estimates for Nkarta's FY2026 earnings at ($1.29) EPS.</p>
<div class="lb-trans"><p>Nkarta, Inc.（纳斯达克代码：NKTX - 免费报告）- 威廉·布莱尔的投资分析师在 11 月 11 日星期二向投资者发布的研究报告中上调了对 Nkarta 2025 财年每股收益的预期。威廉·布莱尔的分析师 S. Corwin 现在预计该公司 2025 财年每股收益为（$1.36），高于之前预测的（$1.38）。市场普遍预计 Nkarta 当前全年的每股收益为（$1.70）。威廉·布莱尔还对 Nkarta 2026 财年的每股收益进行了预测，预计为（$1.29）。</p>
</div><p>Nkarta (NASDAQ:NKTX - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.03.</p>
<div class="lb-trans"><p>Nkarta（纳斯达克代码：NKTX - 获取免费报告）在 11 月 10 日星期一发布了季度财报。该公司报告的季度每股收益为（$0.29），超出市场普遍预期的（$0.32）$0.03。</p>
</div><p>Other equities research analysts have also issued research reports about the company. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Nkarta in a research note on Friday, October 31st. Needham &amp; Company LLC restated a &#34;buy&#34; rating and issued a $10.00 target price on shares of Nkarta in a report on Wednesday, August 13th. Wall Street Zen raised shares of Nkarta from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, October 25th. Finally, Stifel Nicolaus dropped their price target on shares of Nkarta from $12.00 to $11.00 and set a &#34;buy&#34; rating for the company in a research report on Tuesday. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $13.25.</p>
<div class="lb-trans"><p>其他股票研究分析师也对该公司发布了研究报告。Weiss Ratings 在 10 月 31 日星期五的研究报告中重新发布了对 Nkarta 股票的 “卖出（d-）” 评级。Needham &amp; Company LLC 在 8 月 13 日星期三的报告中重申了对 Nkarta 的 “买入” 评级，并给出了$10.00 的目标价。华尔街 Zen 在 10 月 25 日星期六的研究报告中将 Nkarta 的评级从 “卖出” 上调至 “持有”。最后，Stifel Nicolaus 在周二的研究报告中将 Nkarta 的目标价从$12.00 下调至$11.00，并对该公司设定了 “买入” 评级。四位投资分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为$13.25。</p>
</div><p><strong>Get Our Latest Stock Analysis on Nkarta</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Nkarta 的最新股票分析</strong></p>
</div><h2>Nkarta Stock Down 2.5%</h2>
<div class="lb-trans"><h2>Nkarta 股票下跌 2.5%</h2>
</div><p>NASDAQ NKTX opened at $1.96 on Thursday. The company has a 50-day simple moving average of $2.13 and a two-hundred day simple moving average of $2.01. Nkarta has a 12-month low of $1.31 and a 12-month high of $3.18. The firm has a market cap of $139.22 million, a price-to-earnings ratio of -1.42 and a beta of 0.86.</p>
<div class="lb-trans"><p>纳斯达克 NKTX 在星期四开盘价为$1.96。该公司的 50 日简单移动平均为$2.13，200 日简单移动平均为$2.01。Nkarta 的 12 个月低点为$1.31，12 个月高点为$3.18。该公司的市值为$139.22 百万，市盈率为-1.42，贝塔值为 0.86。</p>
</div><h2>Institutional Investors Weigh In On Nkarta</h2>
<div class="lb-trans"><h2>机构投资者对 Nkarta 的看法</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the stock. Savant Capital LLC purchased a new position in shares of Nkarta during the second quarter valued at about $36,000. SG Americas Securities LLC boosted its position in Nkarta by 35.0% during the 3rd quarter. SG Americas Securities LLC now owns 23,663 shares of the company's stock valued at $49,000 after acquiring an additional 6,141 shares in the last quarter. CWM LLC boosted its position in Nkarta by 3,437.3% during the 1st quarter. CWM LLC now owns 28,157 shares of the company's stock valued at $52,000 after acquiring an additional 27,361 shares in the last quarter. Bailard Inc. purchased a new position in shares of Nkarta during the 3rd quarter worth approximately $61,000. Finally, Cerity Partners LLC bought a new position in shares of Nkarta in the 1st quarter worth approximately $55,000. 80.54% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近调整了对该股票的持有。Savant Capital LLC 在第二季度购买了价值约$36,000 的 Nkarta 新头寸。SG Americas Securities LLC 在第三季度将其在 Nkarta 的持仓增加了 35.0%。SG Americas Securities LLC 目前拥有 23,663 股该公司股票，价值$49,000，此前在上个季度又增持了 6,141 股。CWM LLC 在第一季度将其在 Nkarta 的持仓增加了 3,437.3%。CWM LLC 目前拥有 28,157 股该公司股票，价值$52,000，此前在上个季度又增持了 27,361 股。Bailard Inc.在第三季度购买了价值约$61,000 的 Nkarta 新头寸。最后，Cerity Partners LLC 在第一季度购买了价值约$55,000 的 Nkarta 新头寸。80.54% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About Nkarta</h2>
<div class="lb-trans"><h2>关于 Nkarta</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.</p>
<div class="lb-trans"><p>Nkarta, Inc.是一家临床阶段的生物制药公司，开发和商业化用于癌症和自身免疫疾病治疗的自然杀伤细胞疗法。该公司的主要产品候选者是 NKX019，一种靶向 CD19 抗原的嵌合抗原受体 - 自然杀伤细胞（CAR NK），目前正在进行针对复发/难治性（r/r）非霍奇金淋巴瘤的 1 期临床试验，以及针对狼疮性肾炎的治疗。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Nkarta</li>
<li>Differences Between Momentum Investing and Long Term Investing</li>
<li>3 Reasons On Holding’s Sell-Off Is Over and New Highs Are Coming</li>
<li>What is MarketRank™? How to Use it</li>
<li>As Warren Buffett Nears His Exit, Berkshire's Amassed Record Cash</li>
<li>3 Monster Growth Stocks to Buy Now</li>
<li>Rare Earth Stocks: The Truce That Isn't a Truce</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 Nkarta 更好</li>
<li>动量投资与长期投资的区别</li>
<li>关于 Holding 的抛售结束的三大理由及新高即将到来</li>
<li>什么是 MarketRank™？如何使用它</li>
<li>随着沃伦·巴菲特接近退出，伯克希尔积累了创纪录的现金</li>
<li>现在购买的三只巨型成长股</li>
<li>稀土股票：并非真正的停火</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TktUWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=NKTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Nkarta Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Nkarta 吗？</h2>
</div><p>Before you consider Nkarta, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Nkarta 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nkarta wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Nkarta 并不在名单上。</p>
</div><p>While Nkarta currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Nkarta 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

William Blair 发布了 Nkarta 的 2025 财年收益预估